This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Implied Volatility Surging for BD (BDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BD (BDX) stock based on the movements in the options market lately.
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
BD's (BDX) Latest Collaboration to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
by Zacks Equity Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
by Zacks Equity Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.83% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS
by Debanjana Dey
The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.
Zacks Industry Outlook Highlights Becton, Dickinson and Company, Patterson Companies and SmileDirectClub
by Zacks Equity Research
Becton, Dickinson and Company, Patterson Companies and SmileDirectClub are part of Zacks Industry Outlook article.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.
3 Dental Supplies Stocks to Buy Amid Industry Headwinds
by Zacks Equity Research
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, PDCO and SDC.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BDX or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
Earnings Season Scorecard and Fresh Analyst Research Reports for Chevron, Adobe & AMD
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Chevron (CVX), Adobe (ADBE), AMD (AMD) and 16 other stocks.
3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
BDX vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
BD's (BDX) Latest Collaboration to Enhance Patient Care
by Zacks Equity Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.